SEC Form 4 · accession 0001209191-18-039693
ARATANA THERAPEUTICS, INC. · PETX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent Standridge
Officer — Chief Operating Officer
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001509190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 25, 2018 | S | 10,000 | $4.5644 | D | 99,967 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2017. This sale constitutes the final sale under such trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.